Lenz Therapeutics Inc.

06/10/2025 | Press release | Distributed by Public on 06/10/2025 14:56

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
LENZ Therapeutics, Inc. (the "Company") held its 2025 annual meeting of stockholders on June 10, 2025 (the "Annual Meeting"). Of the 27,544,520 shares of the Company's common stock outstanding as of the record date of April 14, 2025, 17,983,676 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:
1.Election of Class III and Class I Directors. The following nominees were elected to serve as Class III directors to hold office until the Company's 2027 annual meeting of stockholders and Class I directors to hold office until the Company's 2028 annual meeting of stockholders, or until their respective successor has been duly elected and qualified:
Nominee Class Votes For Votes Withheld Broker Non-Votes
Kimberlee C. Drapkin III 12,390,015 3,157,989 2,435,672
Zach Scheiner III 12,714,299 2,833,705 2,435,672
Frederic Guerard I 15,369,962 178,042 2,435,672
James McCollum I 15,397,013 150,991 2,435,672
2.Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified based on the following results of voting:
Votes For Votes Against Abstentions Broker Non-Votes
17,979,770 2,698 1,208 -
Lenz Therapeutics Inc. published this content on June 10, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 10, 2025 at 20:56 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io